Loading clinical trials...

Robot-Assisted vs. Video-Assisted Lobectomy for NSCLC (RAVAR) | Clinical Trials | Clareo Health

RECRUITINGNA

Robot-Assisted vs. Video-Assisted Lobectomy for NSCLC (RAVAR)

Robot-Assisted Versus Video-Assisted Lobectomy for Non-Small Cell Lung Cancer (RAVAR): A Multicenter, Open-Label, Randomized, Non-Inferiority Trial

NCT06524427•Sun Yat-sen University

View on ClinicalTrials.gov

Summary

Video-assisted thoracic surgery (VATS) has been recommended by clinical guidelines as one of the preferred surgeries for early-stage non-small cell lung cancer (NSCLC) for many years. However, VATS has inherent drawbacks, so at the beginning of this century, robotic-assisted thoracoscopic surgery (RATS) was first applied for lung resection. In recent years, RATS has developed rapidly, but there are still many unsolved scientific problems in the field of RATS. Thus, a multicenter prospective randomized controlled trial was conducted with stage I-II NSCLC patients as the study subject and 5-year DFS as the primary endpoint to compare the short-term and long-term outcomes of RATS and VATS in the treatment of early-stage NSCLC.

Eligibility

Age

18 - 80 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Age from 18 to 80 years old;
•2. Patients with blood pressure\<160/100mmHg, 5.6\<blood glucose\<11.2mmol/L, major organs function normally: (1) Goldman index between grade 1 and 2; (2) Predicted forced expiratory volume in 1s (FEV1) \>= 40 % and diffusing capacity of the lung for carbon monoxide (DLCO) \>= 40 %; (3) total bilirubin \<= 1.5 upper limit of normal; (4) Alanine aminotransferase (ALT)/Aspartate aminotransferase (AST) \<= 2.5 upper limit of normal; (5) creatinine \<= 1.25 upper limit of normal and creatinine clearance rate (CCr) \>= 60ml/min;
•3. The first clinical diagnosis before surgery was non-small cell lung cancer, including adenocarcinoma, squamous cell carcinoma, large cell carcinoma, and other unknown types;
•4. Clinical stage T1-2N0-1 (cI-II): Maximum diameter of tumor \<= 5cm and short diameter of mediastinal lymph node \<= 1cm in thin layer CT;
•5. Performance status of Eastern Cooperative Oncology Group (ECOG) 0-1;
•6. All relevant examinations were completed within 28 days before the operation;
•7. Patients who understand this study and have signed an approved Informed Consent.

Exclusion Criteria

•1. Patients with radiotherapy, chemotherapy, targeted therapy, or immunotherapy before surgery.
•2. Patients with the previous history of other malignancies;
•3. Patients with secondary primary cancer when enrolled;
•4. Patients diagnosed as pure ground glass opacity (GGO) before surgery;
•5. Patients diagnosed as mixed GGO whose solid part \<= 50% and Maximum diameter of tumor \<= 2cm;
•6. Patients with small cell lung cancer;
•7. Patients with prior unilateral open thoracic surgical procedures;
•8. Woman who is pregnant or breastfeeding;
•9. Patients with interstitial pneumonia, pulmonary fibrosis, or severe emphysema;
•10. Patients with an active bacterial or fungal infection that is difficult to control;
+2 more criteria

Locations (23)

First Affiliated Hospital of Chongqing Medical University

Chongqing, Chongqing Municipality, China

Gansu Provincial Hospital

Lanzhou, Gansu, China

The Second Hospital of Lanzhou University

Lanzhou, Gansu, China

Sun Yat-sen University Cancer Center

Guangzhou, Guangdong, China

Guangdong Provincial People's Hospital

Guangzhou, Guangdong, China

Shenzhen People's Hospital

Shenzhen, Guangdong, China

Shenzhen Third People's Hospital

Shenzhen, Guangdong, China

Guangxi Nanxishan Hospital

Guilin, Guangxi, China

The First Affiliated Hospital of Zhengzhou University

Zhengzhou, Henan, China

Wuhan Union Hospital

Wuhan, Hubei, China

Key Dates

Start Date

August 25, 2020

Primary Completion Date

December 31, 2030

Completion Date

December 31, 2030

Last Updated

December 31, 2025

Enrollment

1,124

ESTIMATED participants

Conditions

Non Small Cell Lung Cancer

Interventions

Robot-assisted lobectomy

PROCEDURE

Video-assisted lobectomy

PROCEDURE

Contacts

Hao-Xian Yang, M.D.

CONTACT

+86-020-87343628 yanghx@sysucc.org.cn

Mu-Zi Yang, M.D.

CONTACT

+86-020-87341456 yangmz@sysucc.org.cn

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

NCT06066138

Locally Advanced Alveolar Soft Part SarcomaMetastatic Alveolar Soft Part Sarcoma+8 more

View study

RECRUITING

Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors

NCT07485114

Renal Cell Carcinoma (Kidney Cancer)Non Small Cell Lung Cancer+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 31, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Robot-Assisted vs. Video-Assisted Lobectomy for NSCLC (RAVAR)

Inclusion Criteria

Exclusion Criteria

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors

Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.

Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)

A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study)